Trial Profile
A phase1, Randomized, Double-blind, Placebo-controlled, Two-part, Sequential Ascending Single and Multiple Dose Study to Investigate the Safety, Tolerability and the PK and PD Profile of OPS-2071 in Healthy Male Korean Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs OPS 2071 (Primary)
- Indications Intestinal infections
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical
- 25 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2014 New trial record